Brii Bio announces positive end-of-treatment results from phase 2b ENRICH & ENHANCE studies to treat chronic hepatitis B: Durham, North Carolina Monday, July 6, 2026, 18:00 Hrs [I ...
Vietnam Investment Review on MSN
Brii Bio phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from ...
Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — ...
Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from ...
The owner of five dogs who mauled a man to death in March 2025 pleaded guilty to negligent homicide and multiple counts of ...
This project introduces ALMA (Automated meta-Learning of Memory designs for Agentic systems), a framework that meta-learns memory designs to replace hand-engineered memory designs, therefore ...
3 July 2026 AstraZeneca and CSPC Pharmaceutical have added renal disease to a growing list of areas covered by their research tie-ups, with a new collaboration to develop small nucleic acid drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results